Johnson Fistel, Announces Investigations of INC Research Holdings, Inc., Acorda Therapeutics, Inc., and Shopify Inc.; Investors Encouraged to Contact Firm

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Johnson Fistel, Announces Investigations of INC Research Holdings, Inc., Acorda Therapeutics, Inc., and Shopify Inc.; Investors Encouraged to Contact Firm

PR Newswire

SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against INC Research Holdings, Inc., Acorda Therapeutics, Inc., and Shopify Inc. as detailed below:

INC Research Holdings, Inc.

Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by INC Research Holdings, Inc. ("INC Research") (NASDAQ: INCR).

On November 9, 2017, INC Research reported its first financial results after merging with inVentiv Health. INC Research's combined results were adversely impacted by merger-related expenses, an impairment charge and increased amortization expenses. Following the news, INC Research stock fell significantly.

If you purchased INC Research common stock between May 1, 2017 and November 9, 2017 and are interested in learning more about your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Acorda Therapeutics, Inc.
Shareholder Rights Law Firm Johnson Fistel, LLP today announced that it is investigating whether certain officers or directors of Acorda Therapeutics, Inc. ("Acorda") (NASDAQ: ACOR) violated federal or state laws.

A Securities Class Action Complaint was filed on behalf of those who purchased securities of Acorda between April 18, 2016 through November 14, 2017.

According to the lawsuit, defendants during the Class Period made materially false and misleading statements and failed to disclose that: (1) tozadenant entailed significant undisclosed safety risks; (2) accordingly, Acorda had overstated tozadenant's approval prospects and commercial viability; (3) for the foregoing reasons, Acorda had likewise overstated the benefits of the Biotie Acquisition; and (4) as a result, Acorda's shares traded at artificially inflated prices during the Class Period. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as a lead plaintiff, you must move the Court no later than January 17, 2018

If you are a long-term shareholder of Acorda shares and continuously held shares before April 18, 2016, you may have standing to hold Acorda harmless from the damage the officers and directors may have caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are an Acorda shareholder and are interested in learning more about your legal rights and remedies, please contact Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Shopify Inc.
Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Shopify Inc. ("Shopify") (NYSE: SHOP) and certain of its officers.

On October 4, 2017, Citron Research published a report describing Shopify as "a completely illegal get-rich quick scheme" and alleges that Shopify is engaging in business practices that are prohibited by the Federal Trade Commission. Following this news, Shopify's stock dropped over 11.00%.

If you have information that could assist in this investigation, including former employees and others, or if you are a Shopify shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If you email, please include your phone number.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

View original content:http://www.prnewswire.com/news-releases/johnson-fistel-announces-investigations-of-inc-research-holdings-inc-acorda-therapeutics-inc-and-shopify-inc-investors-encouraged-to-contact-firm-300562525.html

SOURCE Johnson Fistel, LLP

Copyright CNW Group 2017

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).